Mar
24
2021
On demand

FectoVIR®-AAV, the new tool to enhance recombinant AAV production for gene therapy

Ever-increasing demand for clinical and commercial-scale recombinant adeno-associated viral (rAAV) vector manufacturing has brought into sharp focus the need for new technological innovation to drive the requisite bioprocess productivity and efficiency gains.    

In this webinar, Viralgen - a CDMO born as a joint venture between Askbio and Columbus Venture Partners, and recently acquired by Bayer - will discuss its approach to driving the industrialization of rAAV vector production, and present recent data obtained with the FectoVIR®-AAV transfection reagent for the production of rAAV in its Pro10™ cell line.

Attendees will learn:

  • How to optimize AAV productions based on improved transfection tools.
  • How to improve transfection reproducilbility and rAAv production at different production scales.

Mathieu Porte

Bioproduction R&D Manager, Polyplus-transfection®

Mathieu Porte is Bioproduction R&D Manager at Polyplus-transfection®. After obtaining his Biotechnology Engineering Degree from the renowned European School ESBS (Strasbourg, France), he worked as Research Assistant at New England Biolabs and UCSF. He joined Polyplus-transfection® in 2009. During 10 years in the Bioproduction R&D group, he carried out the development of several innovative transfection solutions dedicated to biomanufacturing.

Valerie Lang

USP Manager, Viralgen VC

Valerie Lang is USP Manager at Viralgen Vector Core. She obtained her PhD in molecular and cellular pharmacology in the University of Pierre and Marie Curie (Paris, France). She has extensive experience in cell culture and manufacturing. She joined Viralgen in 2017 and has been responsible for designing, implementing, and optimizing industrial AAV processes and manufacturing.

Elisa Da Silva Ferrada

Upstream Process Development Lead Scientist, Viralgen VC

Elisa da Silva Ferrada is USP Process Development Lead Scientist at Viralgen Vector Core (VVC). Got her PhD at University of Basque Country in Molecular Biology and Biomedicine. Joined to VVC in 2019 to work on USP process development for AAV production


SPEAKERS

Mathieu Porte
BioProduction R&D Manager, Polyplus-transfection
Elisa Da Silva Ferrada
USP Process Development Lead Scientist, Viralgen Vector Core (VVC)
Valerie Lang
Production Manger, Viralgen VC

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
8
Hrs
36
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
16
Hrs
36
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
8
Hrs
36
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
16
Hrs
36
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
8
Hrs
36
Min
Register